Posts

Anki Malmborg Hager

SenzaGen invited to prestigious meeting at ICCVAM, US

Today, Tuesday the 27 September SenzaGen is invited to participate at a science Committee Meeting of the American organization ICCVAM *, which promotes the development of alternative methods to replace animal testing. Together with its US partner, Burleson Research Technologies, Inc., SenzaGen will participate in the official program and make a statement about Skin Sensitization Testing, the importance of secure and robust tests for classification of chemical substances with the ability to identify the potential of a substance causing allergy.

US ICCVAM is a permanent committee consisting of representatives from 15 federal regulatory and research agencies that requires, uses, generates, or disseminates toxicological and safety testing information to replace animal experiments. ICCVAM take expert advice from SACATM **, whose members include stakeholders from regulated industries, animal welfare organizations, academia, U.S. state or international regulatory bodies, and companies or organizations that develop, market or use test methods.

In connection with the SACATM meeting SenzaGen was invited together with their partner Burleson Research Technologies to make a statement in the session for Skin Sensitization Testing.

“It is a great achievement for us that we now have the opportunity, together with our partner Burleson Research Technologies, to give our views on the future development of testing in the U.S and to present GARD, before members of the prestigious SACATM. This shows that GARD is already on their radar, as the next-generation of sensitization testing. Only by cooperating at the highest level can we set a new industry standard for allergy testing in the US market, says Anki Malmborg Hager,” CEO of SenzaGen.

The ICCVAM meeting is being held in Research Triangle Park, North Carolina on Tuesday, 27 September and the CEO of SenzaGen AB, Anki Malmborg Hager will make her statement and give the recommendations in the session ICCVAM Roadmap to Skin Sensitization Testing at 11.25 am (EDT).

* ICCVAM: The Interagency Coordinating Committee on the Validation of Alternative Methods
** SACATM: Scientific Advisory Committee on Alternative Toxicological Methods

For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
Mail: amh@senzagen.com
Phone: +46 768 284822

 

About GARD
By analyzing 200 and 389 markers, depending on the test, GARD generates massive amounts of data and delivers results with 90 % prediction accuracy. This can be compared to the gold standard, animal tests in mice, that provides 72 % prediction. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance is an allergen.

About SenzaGen
SenzaGen provides dermal and respiratory in vitro testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test, GARD, is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

SenzaGen Invited to High-Tech Health Research Expo in Washington, D.C.

SenzaGen have been invited by U.S. Representative Tom Marino to present the company’s technology at the High-Tech Health Research Expo in Washington, D.C., where SenzaGen will meet US congressmen and federal procurement officials interested in the use of high-tech human-focused methods to replace animal tests. The Expo takes place on September 15th, 2016.

The High-Tech Health Research Expo is organized by U.S. Representative Tom Marino who has been an outspoken leader for increased investments in this sector of the healthcare industry. The market for alternative and animal-free test methods is growing rapidly and there is a great interest for its benefits – scientifically and economically as well as from a public health perspective.

“The provisions to reduce animal testing under the reformed Toxic Substances Control Act (TSCA) will ensure an even bigger interest in the field and SenzaGen has a natural fit in this with its test being validated for the international market by OECD says Brian Rogers,” CEO of SenzaGen Inc.

At the Expo, selected companies will have the opportunity to present their technologies to Members of congress, congressional staffers and other representatives from different government agencies.  The goal of the Expo is to help advance this sector of the healthcare industry by creating an opportunity for the best and the brightest in the field to efficiently reach the largest number of decision-makers at once.

“We are very proud to participate. Now, our US subsidiary will have the opportunity to reach out to some of the most influential members of Congress, who really have a say in our industry. We see it as a confirmation of our US investment and our unique test method GARD says Anki Malmborg-Hager,” CEO of SenzaGen Sweden.

High-Tech Health Care Expo takes place at the Cannon House Office Building in Washington, DC on September 15, 2016. SenzaGen will participate with their U.S:  employees, and will have a stand where the company will demonstrate the latest technique to replace animal testing when performing allergy testing of chemicals and chemical ingredients.

 

For more information:

Anki Malmborg Hager, CEO
amh@senzagen.com
SE: +46 768 284822

Brian Rogers, Ph D, CEO US
brian.rogers@senzagen.com
US: +1 530 304 7648, +1 530 867 5600

 

About SenzaGen
SenzaGen provides in vitro dermal and respiratory testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test GARD is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

About GARD
By analyzing 200 and 389 genomic markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice that provide 72 % accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy.

SenzaGen establishes subsidiary in the US

To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California.

SenzaGen, which develops and implements non-animal allergy tests of chemicals and proteins, for the chemical, pharmaceutical and cosmetic industries, expands its sales organization and prepares the company for an IPO in 2017. Senzagen, a Lund University Department of Immunotechnology spin-out was recently recognized as one of Sweden’s most promising young and innovative companies.

“In line with our strategy to establish a commercial presence in key markets, Senzagen has established a subsidiary in the US. The US represents the world’s largest pharmaceutical and chemicals markets, and one of the largest within cosmetics. To capture market share, it is crucial that we have a local presence, says Anki Malmborg-Hager”, CEO of SenzaGen AB.

Responsible for Senzagen’s US operations will be toxicologist Dr. Brian Rogers as US CEO, and Head of business development will be immunologist Dr. Sandra Reynoso.

“Nearly 50% of all animal research experiments today are performed in the US, and we want to be there to help replace these tests and offer the market a better and much safer test with our GARD. Together with our local team and their strong network, I look forward to building SenzaGen’s brand as the market leader in allergy testing in the US”, says Anki Malmborg-Hager.

 

For more information, please contact:
Anki Malmborg Hager, Ph D, CEO,
E-mail: amh@senzagen.com
SE: +46 768 284822
Brian Rogers
E-mail: brian.rogers@senzagen.com
US: +1 530 867 5600

 

About SenzaGen
SenzaGen provides in vitro dermal and respiratory testing for the cosmetic, chemical and pharmaceutical industries replacing the need for animal testing. The company’s unique test GARD is based on research from the Department of Immunotechnology at Lund University. SenzaGen is based at Medicon Village in Lund, Sweden.

About GARD
By analyzing 200 and 389 genomic markers, depending on the test, instead of 1-2 markers as competing methods, GARD delivers results with 90 % accuracy. This can be compared to the golden standard, animal tests on mice, that provide 72 % accuracy. SenzaGen’s test also has the ability to measure potency (strength) of a substance and can thus determine the degree to which a substance cause allergy.